Arrowhead Pharmaceuticals, Inc.
As of Oct 22, 2026, Arrowhead Pharmaceuticals is in Stage 3, the topping phase, now in week 5 (since Sep 23, 2026). It closed at $58.36, 34.9% below its 52-week high and below its 200-day average, which is falling.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ARWR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ARWR among Biotechnology85th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …85 | ARWR | Stage 3 · wk 5 | 87 | −12.8% |
Arrowhead Pharmaceuticals: quick answers
What stage is Arrowhead Pharmaceuticals in?
As of Oct 22, 2026, Arrowhead Pharmaceuticals (ARWR) is in Stage 3, the topping phase. It entered Stage 3 on Sep 23, 2026 and is in week 5. What the four stages mean
Is Arrowhead Pharmaceuticals in an uptrend?
Its uptrend has stalled. Arrowhead Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 18.8% below its 200-day average, which is falling.
How far is Arrowhead Pharmaceuticals from its 52-week high?
Arrowhead Pharmaceuticals closed at $58.36 on Oct 22, 2026, 34.9% below its 52-week high of $89.59. Its 52-week low is $37.35.
How has Arrowhead Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Arrowhead Pharmaceuticals is up 53.5% over the past year and down 13.9% so far in 2026.
Which sector and industry is Arrowhead Pharmaceuticals in?
Arrowhead Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.